Status:
COMPLETED
An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
All Genders
20-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine if AZD2516 binds to mGluR5 receptors in the brain. This will then help to make accurate predictions of efficacy and dosing in the future development programme...
Eligibility Criteria
Inclusion
- Normal MRI scan
- Healthy male or non-fertile females
- Body Mass Index (BMI) of ≥19 to ≤28 kg/m2 and weight of ≥50 to ≤100 kg
Exclusion
- History of disease or condition that may interfere with the objectives of the study
- History of previous or ongoing psychiatric disease/condition
- Concomitant medication
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2009
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00892944
Start Date
April 1 2009
End Date
October 1 2009
Last Update
October 28 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Stockholm, Sweden